StockCalc Blog

Clearwater Paper (CLW:NYS) Fundamental Valuation Report

By admin Posted on April 22, 2021 Posted in Fundamental Valuation Report

Fundamental Valuation Report Clearwater Paper(CLW:NYS) Basic Materials:Paper & Paper Products This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$34.98 (USD) 04/21/2021 Weighted Valuation$40.04 (USD) Overall RatingUndervalued by 14.5% Valuation Models …

Clearwater Paper (CLW:NYS) Fundamental Valuation Report Read more »

Chimerix (CMRX:NAS) Fundamental Valuation Report

By admin Posted on April 22, 2021 Posted in Fundamental Valuation Report

Fundamental Valuation Report Chimerix(CMRX:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$8.25 (USD) 04/21/2021 Weighted Valuation$6.79 (USD) Overall RatingOvervalued by 17.8% Valuation Models Comparables: $6.79 (USD) Valuation Methods This …

Chimerix (CMRX:NAS) Fundamental Valuation Report Read more »

CenterPoint Energy (CNP:NYS) Fundamental Valuation Report

By admin Posted on April 22, 2021 Posted in Fundamental Valuation Report

Fundamental Valuation Report CenterPoint Energy(CNP:NYS) Utilities:Utilities – Regulated Electric This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$24.29 (USD) 04/21/2021 Weighted Valuation$24.20 (USD) Overall RatingFairly valued to slightly Overvalued by 0.4% …

CenterPoint Energy (CNP:NYS) Fundamental Valuation Report Read more »

CCL Industries (CCL.B:TSE) Fundamental Valuation Report

By admin Posted on April 21, 2021 Posted in Fundamental Valuation Report

Fundamental Valuation Report CCL Industries(CCL.B:TSE) Consumer Cyclical:Packaging & Containers This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$69.10 (CAD) 04/20/2021 Weighted Valuation$71.25 (CAD) Overall RatingFairly valued to slightly Undervalued by 3.1% …

CCL Industries (CCL.B:TSE) Fundamental Valuation Report Read more »

Cross Country Healthcare (CCRN:NAS) Fundamental Valuation Report

By admin Posted on April 21, 2021 Posted in Fundamental Valuation Report

Fundamental Valuation Report Cross Country Healthcare(CCRN:NAS) Industrials:Staffing & Employment Services This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$12.67 (USD) 04/20/2021 Weighted Valuation$11.51 (USD) Overall RatingOvervalued by 9.1% Valuation Models …

Cross Country Healthcare (CCRN:NAS) Fundamental Valuation Report Read more »

Cidara Therapeutics (CDTX:NAS) Fundamental Valuation Report

By admin Posted on April 21, 2021 Posted in Fundamental Valuation Report

Fundamental Valuation Report Cidara Therapeutics(CDTX:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$2.03 (USD) 04/20/2021 Weighted Valuation$1.92 (USD) Overall RatingOvervalued by 5.4% Valuation Models Comparables: $1.67 (USD) (in order …

Cidara Therapeutics (CDTX:NAS) Fundamental Valuation Report Read more »

Cerus (CERS:NAS) Fundamental Valuation Report

By admin Posted on April 21, 2021 Posted in Fundamental Valuation Report

Finance trade manager analysing stock market indicators for best investment strategy, financial data and charts with business buildings in background

Fundamental Valuation Report Cerus(CERS:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$5.84 (USD) 04/20/2021 Weighted Valuation$5.90 (USD) Overall RatingFairly valued to slightly Undervalued by 1.0% Valuation Models Adjusted Book …

Cerus (CERS:NAS) Fundamental Valuation Report Read more »

Compugen (CGEN:NAS) Fundamental Valuation Report

By admin Posted on April 21, 2021 Posted in Fundamental Valuation Report

Fundamental Valuation Report Compugen(CGEN:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$8.25 (USD) 04/20/2021 Weighted Valuation$8.22 (USD) Overall RatingFairly valued to slightly Overvalued by 0.4% Valuation Models Comparables: $8.62 (USD) …

Compugen (CGEN:NAS) Fundamental Valuation Report Read more »

Coherus BioSciences (CHRS:NAS) Fundamental Valuation Report

By admin Posted on April 21, 2021 Posted in Fundamental Valuation Report

Fundamental Valuation Report Coherus BioSciences(CHRS:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$14.27 (USD) 04/20/2021 Weighted Valuation$27.53 (USD) Overall RatingUndervalued by 93.0% Valuation Models Discounted Cash Flow: $27.53 (USD) …

Coherus BioSciences (CHRS:NAS) Fundamental Valuation Report Read more »

Cigna (CI:NYS) Fundamental Valuation Report

By admin Posted on April 21, 2021 Posted in Fundamental Valuation Report

Fundamental Valuation Report Cigna(CI:NYS) Healthcare:Healthcare Plans This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$253.37 (USD) 04/20/2021 Weighted Valuation$260.40 (USD) Overall RatingFairly valued to slightly Undervalued by 2.8% Valuation Models Comparables: $278.15 …

Cigna (CI:NYS) Fundamental Valuation Report Read more »

Notice to User:

Risk Disclosure:
Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results.

Hypothetical Performance Disclosure:
Hypothetical performance results have many inherent limitations, some of which are described below. no representation is being made that any account will or is likely to achieve profits or losses similar to thoseshown; in fact, there are frequently sharp differences between hypothetical performance results and the actual results subsequently achieved by any particular trading program. One of the limitations of hypothetical performance results is that they are generally prepared with the benefit of hindsight. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. for example, the ability to withstand losses or to adhere to a particular trading program in spite of trading losses are material points which can also adversely affect actual trading results. There are numerous other factors related to the markets in general or to the implementation of any specific trading program which cannot be fully accounted forin the preparation of hypothetical performance results and all which can adversely affect trading results.

Live Trades Disclosure:
This presentation is for educational purposes only and the opinions expressed are those of the presenter only. All trades presented should be considered hypothetical and should not be expected to be replicated in a live trading account.